| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..10011406A |
| P356 | DOI | 10.1073/PNAS.1936664100 |
| P932 | PMC publication ID | 208770 |
| P698 | PubMed publication ID | 13679574 |
| P5875 | ResearchGate publication ID | 9886399 |
| P50 | author | Michel Bouvier | Q38326685 |
| Stephane Angers | Q42889228 | ||
| P2093 | author name string | Guy Rousseau | |
| Trudy Kohout | |||
| Pascale G Charest | |||
| Graciela Piñeyro | |||
| Mounia Azzi | |||
| P2860 | cites work | Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes | Q22008730 |
| beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2 | Q22253360 | ||
| The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor | Q22253381 | ||
| Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds | Q24605173 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3 | Q28138462 | ||
| Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system | Q28204412 | ||
| beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking | Q28507206 | ||
| Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor | Q29618735 | ||
| Functional desensitization to isoproterenol without reducing cAMP production in canine failing cardiocytes | Q32031417 | ||
| Inverse, protean, and ligand-selective agonism: matters of receptor conformation | Q33938998 | ||
| Overview of recent clinical trials in heart failure: what is the current standard of care? | Q34156863 | ||
| Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors | Q34389558 | ||
| Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. | Q34467657 | ||
| Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET) | Q35120622 | ||
| Morphine-activated opioid receptors elude desensitization by β-arrestin | Q36280218 | ||
| Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness | Q36514037 | ||
| Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. | Q37105461 | ||
| The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex | Q37273521 | ||
| Regulation of adenylyl cyclase-coupled beta-adrenergic receptors | Q39293330 | ||
| Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer | Q40702442 | ||
| beta 2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf | Q40875727 | ||
| Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization | Q40920202 | ||
| Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling | Q40931328 | ||
| Activation of mitogen-activated protein kinase by the bradykinin B2 receptor is independent of receptor phosphorylation and phosphorylation-triggered internalization. | Q40947833 | ||
| The Endothelin Subtype A Receptor Undergoes Agonist- and Antagonist-Mediated Internalization in the Absence of Signaling1 | Q41030112 | ||
| Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. | Q41079862 | ||
| Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. | Q41080173 | ||
| Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization | Q41176691 | ||
| Inverse agonist activity of beta-adrenergic antagonists. | Q41485351 | ||
| Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor | Q43586918 | ||
| AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. | Q43845849 | ||
| Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus | Q47866757 | ||
| Analysis of the Gs/Mitogen-activated Protein Kinase Pathway in Mutant S49 Cells | Q48034450 | ||
| The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists | Q52926779 | ||
| NK1 Receptor Fused to beta -Arrestin Displays a Single-Component, High-Affinity Molecular Phenotype | Q57065434 | ||
| G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor | Q71921039 | ||
| Novel S49 lymphoma variants with aberrant cyclic AMP metabolism | Q72884320 | ||
| Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor | Q73128169 | ||
| Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells | Q74623203 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | G protein-coupled receptor | Q38173 |
| P304 | page(s) | 11406-11411 | |
| P577 | publication date | 2003-09-17 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors | |
| P478 | volume | 100 |
| Q35210020 | 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? |
| Q92664976 | A Brief History of the β-Arrestins |
| Q34321618 | A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine |
| Q34540545 | A Pluridimensional View of Biased Agonism |
| Q39341462 | A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer. |
| Q57152115 | A focus on CXCR4 in Alzheimer's disease |
| Q28476391 | A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors |
| Q42290882 | A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling |
| Q35156778 | A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding. |
| Q36082162 | A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling |
| Q36940130 | Activation of G protein-coupled receptors |
| Q46443857 | Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists |
| Q40226278 | Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase |
| Q37275085 | Activation of intracellular signaling pathways by the murine cytomegalovirus G protein-coupled receptor M33 occurs via PLC-{beta}/PKC-dependent and -independent mechanisms |
| Q36342155 | Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor |
| Q37578268 | Advances in the Development and Application of Computational Methodologies for Structural Modeling of G-Protein Coupled Receptors. |
| Q47717572 | Agonist binding: a multistep process |
| Q28740731 | Agonist-directed desensitization of the β2-adrenergic receptor |
| Q36756874 | Agonist-selective signaling is determined by the receptor location within the membrane domains. |
| Q33604101 | Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications |
| Q38136285 | Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization |
| Q53082766 | Allosteric modulation as a unifying mechanism for receptor function and regulation |
| Q24633877 | Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes |
| Q35720141 | An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. |
| Q38020237 | An update of novel screening methods for GPCR in drug discovery |
| Q41195003 | Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis |
| Q21093341 | Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells |
| Q51513968 | Applying label-free dynamic mass redistribution technology to frame signaling of G protein–coupled receptors noninvasively in living cells |
| Q38114222 | Arrestins in Bone |
| Q41873187 | Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity |
| Q24644106 | Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation |
| Q35133773 | Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes |
| Q29616793 | Beta-arrestins and cell signaling |
| Q24653656 | Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction |
| Q37800215 | Beta-arrestins as regulators of signal termination and transduction: How do they determine what to scaffold? |
| Q33890802 | Beyond desensitization: physiological relevance of arrestin-dependent signaling. |
| Q41059651 | Biased Allostery |
| Q41863995 | Biased agonism |
| Q38209355 | Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective. |
| Q38678404 | Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery? |
| Q41960221 | Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus |
| Q30359656 | Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists |
| Q99574272 | Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases |
| Q40420767 | Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. |
| Q56648552 | Bioluminescence resonance energy transfer-based biosensors allow monitoring of ligand- and transducer-mediated GPCR conformational changes |
| Q92615461 | Bioluminescence resonance energy transfer-based imaging of protein-protein interactions in living cells |
| Q38196401 | Biophysical Detection of Diversity and Bias in GPCR Function |
| Q38817408 | Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones |
| Q45092706 | CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. |
| Q35213405 | CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. |
| Q64900773 | Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors. |
| Q34350478 | Casting a Wider Net: Whole-Cell Assays to Capture Varied and Biased Signaling: Fig 1 |
| Q28578391 | Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors |
| Q37553926 | Cellular assays as portals to seven-transmembrane receptor-based drug discovery |
| Q35964527 | Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18). |
| Q35078148 | Co-expression of GRK2 reveals a novel conformational state of the µ-opioid receptor |
| Q53583903 | Collateral efficacy as a pharmacological problem applied to new drug discovery |
| Q35802560 | Comparative analyses of downstream signal transduction targets modulated after activation of the AT1 receptor by two β-arrestin-biased agonists. |
| Q51620673 | Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions |
| Q36191614 | Composition and function of g protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. |
| Q36880905 | Conformational complexity of G-protein-coupled receptors |
| Q40284486 | Constitutive ERK1/2 activation by a chimeric neurokinin 1 receptor-beta-arrestin1 fusion protein. Probing the composition and function of the G protein-coupled receptor "signalsome". |
| Q24635327 | Crystal structure of the β2 adrenergic receptor-Gs protein complex |
| Q39397383 | Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism |
| Q33964630 | Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist |
| Q42937057 | Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. |
| Q36928951 | Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells |
| Q34774416 | Development and characterization of pepducins as Gs-biased allosteric agonists |
| Q33819496 | Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor |
| Q39366472 | Differential Association of Receptor-Gβγ Complexes with β-Arrestin2 Determines Recycling Bias and Potential for Tolerance of Delta Opioid Receptor Agonists |
| Q42836475 | Differential Inverse Agonism at the Human Muscarinic M3 Receptor |
| Q39225843 | Differential and competitive regulation of human melanocortin 1 receptor signaling by β-arrestin isoforms |
| Q40571692 | Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. |
| Q42378659 | Differential signaling of the endogenous agonists at the beta2-adrenergic receptor |
| Q47852527 | Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs |
| Q34327895 | Discovery of Regulators of Receptor Internalization with High-Throughput Flow Cytometry |
| Q34760546 | Dissociations in the Effects of β2-Adrenergic Receptor Agonists on cAMP Formation and Superoxide Production in Human Neutrophils: Support for the Concept of Functional Selectivity |
| Q42650499 | Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor |
| Q40313388 | Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. |
| Q36786816 | Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. |
| Q33520987 | Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors |
| Q31148493 | Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β₂-adrenergic receptors |
| Q37550019 | Diversity in arrestin function |
| Q37973384 | Drug‐like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function |
| Q39774017 | Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. |
| Q37670366 | Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts |
| Q39188292 | Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells |
| Q42176971 | Effect of a toggle switch mutation in TM6 of the human adenosine A₃ receptor on Gi protein-dependent signalling and Gi-independent receptor internalization |
| Q37085763 | Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma |
| Q46960983 | Emergent biological properties of arrestin pathway-selective biased agonism |
| Q55401243 | Enabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor. |
| Q34664404 | Energy landscapes as a tool to integrate GPCR structure, dynamics, and function |
| Q34837191 | Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling |
| Q47163312 | Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity. |
| Q34660378 | Exploring a role for heteromerization in GPCR signalling specificity |
| Q40892572 | Flow cytometric analysis with a fluorescently labeled formyl peptide receptor ligand as a new method to study the pharmacological profile of the histamine H2 receptor |
| Q31100553 | Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay |
| Q35999789 | Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. |
| Q38636166 | Functional New World monkey oxytocin forms elicit an altered signaling profile and promotes parental care in rats. |
| Q48656806 | Functional Selectivity and Biased Receptor Signaling |
| Q34544364 | Functional competence of a partially engaged GPCR-β-arrestin complex |
| Q35763177 | Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes |
| Q38128127 | Functional selectivity of G-protein-coupled receptors: From recombinant systems to native human cells |
| Q36186182 | Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons |
| Q26752403 | G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs |
| Q36665235 | G Protein-coupled Receptor Biased Agonism |
| Q36692097 | G protein coupled receptor structure and activation |
| Q40281519 | G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer |
| Q35566599 | G-protein-coupled receptors: past, present and future. |
| Q36440674 | GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling |
| Q28659266 | Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct |
| Q37072161 | Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes |
| Q46652753 | High constitutive Akt2 activity in U937 promonocytes: effective reduction of Akt2 phosphorylation by the histamine H2-receptor and the β2-adrenergic receptor |
| Q36280354 | Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. |
| Q34540011 | Identifying Ligand Binding Conformations of the β2-Adrenergic Receptor by Using Its Agonists as Computational Probes |
| Q35046547 | Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor |
| Q28478728 | Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles |
| Q36318886 | Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. |
| Q56648606 | Insights into signaling from the β2-adrenergic receptor structure |
| Q34888305 | Intact MDM2 E3 ligase activity is required for the cytosolic localization and function of β-arrestin2 |
| Q40474801 | Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. |
| Q48657917 | International Workshop at the Nobel Forum, Karolinska Institutet on G protein-coupled receptors: finding the words to describe monomers, oligomers, and their molecular mechanisms and defining their meaning. Can a consensus be reached? |
| Q53503547 | Interrogating 7TM receptors: does texture in the question yield greater texture in the answer? |
| Q36021535 | Inverse agonism: more than reverting constitutively active receptor signaling |
| Q35628363 | Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors |
| Q42950461 | Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism |
| Q40017822 | Label-free optical biosensor for ligand-directed functional selectivity acting on beta(2) adrenoceptor in living cells. |
| Q34473007 | Label-free receptor assays |
| Q37921853 | Lifting the lid on GPCRs: the role of extracellular loops |
| Q38200427 | Ligand bias prevents class equality among beta-blockers. |
| Q38014954 | Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors |
| Q24306565 | Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist |
| Q33730592 | Ligand-directed signalling at beta-adrenoceptors |
| Q33624740 | Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats |
| Q39412016 | Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons |
| Q58435171 | Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9 |
| Q27316989 | Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction |
| Q26991511 | Metaphors, naming and new signaling paradigms by G-protein-coupled receptors |
| Q37610141 | Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. |
| Q38459674 | Minireview: Role of intracellular scaffolding proteins in the regulation of endocrine G protein-coupled receptor signaling |
| Q42838501 | Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery. |
| Q37291841 | Molecular determinants of angiotensin II type 1 receptor functional selectivity |
| Q36773326 | Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors |
| Q39734149 | Morphine-like opiates selectively antagonize receptor-arrestin interactions. |
| Q36880896 | Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. |
| Q36678037 | New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors |
| Q21131252 | Non-Coding RNAs Regulating Morphine Function: With Emphasis on the In vivo and In vitro Functions of miR-190 |
| Q27026973 | Nuclear GPCRs in cardiomyocytes: an insider's view of β-adrenergic receptor signaling |
| Q37317738 | Nuclear β-adrenergic receptors modulate gene expression in adult rat heart |
| Q33735942 | Partially deglycosylated equine LH preferentially activates beta-arrestin-dependent signaling at the follicle-stimulating hormone receptor |
| Q37421226 | Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein |
| Q88577168 | Pepducins as a potential treatment strategy for asthma and COPD |
| Q36138326 | Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor |
| Q36911200 | Pharmacological onomastics: what's in a name? |
| Q33305512 | Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes |
| Q34098252 | Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors |
| Q36954117 | Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. |
| Q28304837 | Physiologic and cardiac roles of beta-arrestins |
| Q37149283 | Pinpointing beta adrenergic receptor in ageing pathophysiology: victim or executioner? Evidence from crime scenes |
| Q42191909 | Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. |
| Q46427567 | Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists |
| Q40220678 | Proline-rich motifs in the parathyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1/2 activation |
| Q36440738 | Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation |
| Q24318701 | Proteinase-activated receptor-2 mediated inhibition of TNFalpha-stimulated JNK activation - A novel paradigm for G(q/11) linked GPCRs |
| Q36089402 | Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo |
| Q39708191 | Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation. |
| Q38571588 | RGS proteins destroy spare receptors: Effects of GPCR-interacting proteins and signal deamplification on measurements of GPCR agonist potency |
| Q40251292 | Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes |
| Q28584024 | Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers |
| Q39377323 | Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. |
| Q39453304 | Regulation of GPCR expression through an interaction with CCT7, a subunit of the CCT/TRiC complex. |
| Q36591603 | Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. |
| Q28266829 | Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors |
| Q36211185 | Role for engagement of β-arrestin2 by the transactivated EGFR in agonist-specific regulation of δ receptor activation of ERK1/2. |
| Q39127195 | Role of PTHrP in human intestinal Caco-2 cell response to oxidative stress |
| Q38296408 | Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription |
| Q44343075 | Sequence-Specific Regulation of Endocytic Lifetimes Modulates Arrestin-Mediated Signaling at the µ Opioid Receptor. |
| Q24300079 | Ser/ Thr residues at α3/β5 loop of Gαs are important in morphine-induced adenylyl cyclase sensitization but not mitogen-activated protein kinase phosphorylation |
| Q33890786 | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery |
| Q36305171 | Seven-transmembrane receptor signaling through beta-arrestin |
| Q39034996 | Signal transduction mechanism of biased ligands at histamine H2 receptors |
| Q34570793 | Signalling profiles of H3 relaxin, H2 relaxin and R3(BΔ23-27)R/I5 acting at the relaxin family peptide receptor 3 (RXFP3) |
| Q36003914 | Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant |
| Q34782818 | Single-molecule force spectroscopy of G-protein-coupled receptors. |
| Q50229537 | Single-molecule imaging reveals the stoichiometry change of β2-adrenergic receptors by a pharmacological biased ligand |
| Q41177127 | Site-specific cleavage of G protein-coupled receptor-engaged beta-arrestin. Influence of the AT1 receptor conformation on scissile site selection |
| Q37823926 | Strategies for the identification of allosteric modulators of G-protein-coupled receptors |
| Q30855022 | Strength of Neisseria meningitidis binding to endothelial cells requires highly-ordered CD147/β2-adrenoceptor clusters assembled by alpha-actinin-4. |
| Q91658861 | Structural Insight into G Protein-Coupled Receptor Signaling Efficacy and Bias between Gs and β-Arrestin |
| Q37854213 | Structural insights into adrenergic receptor function and pharmacology |
| Q35921807 | Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy |
| Q46260678 | Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies |
| Q89210678 | Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation |
| Q26829964 | Targeting G protein coupled receptor-related pathways as emerging molecular therapies |
| Q89623490 | Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments |
| Q47820518 | Teaching an Old Drug New Tricks: Agonism, Antagonism, and Biased Signaling of Pilocarpine through M3 Muscarinic Acetylcholine Receptor |
| Q34964618 | Temporally precise in vivo control of intracellular signalling |
| Q39916587 | The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation |
| Q36569080 | The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice |
| Q91809881 | The Emerging Role of Gβ Subunits in Human Genetic Diseases |
| Q42039032 | The HIV-1 coat protein gp120 regulates CXCR4-mediated signaling in neural progenitor cells |
| Q33651185 | The Structural Basis of G‐Protein‐Coupled Receptor Signaling (Nobel Lecture) |
| Q34203682 | The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation |
| Q35216471 | The design, synthesis and pharmacological characterization of novel β₂-adrenoceptor antagonists. |
| Q47685791 | The development of label-free cellular assays for drug discovery |
| Q34103312 | The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation |
| Q37200963 | The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex |
| Q40220162 | The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors |
| Q24337088 | The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine 2B receptor is a gain of proliferative functions |
| Q37131419 | The origins of diversity and specificity in g protein-coupled receptor signaling |
| Q45261068 | The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism |
| Q38188734 | The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin |
| Q24650706 | The rush to adrenaline: drugs in sport acting on the beta-adrenergic system |
| Q42429572 | The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors |
| Q24670735 | The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors |
| Q55038697 | The state of GPCR research in 2004. |
| Q29616792 | The structure and function of G-protein-coupled receptors |
| Q38782366 | Therapeutic potential and limitations of cholinergic anti-inflammatory pathway in sepsis. |
| Q36773331 | Therapeutic potential of β-arrestin- and G protein-biased agonists. |
| Q28246395 | Transduction of receptor signals by beta-arrestins |
| Q42064855 | Unique interaction pattern for a functionally biased ghrelin receptor agonist |
| Q33640639 | Using ligand-based virtual screening to allosterically stabilize the activated state of a GPCR. |
| Q40649339 | V2 Vasopressin Receptor (V2R) Mutations in Partial Nephrogenic Diabetes Insipidus Highlight Protean Agonism of V2R Antagonists |
| Q28483679 | VENNTURE--a novel Venn diagram investigational tool for multiple pharmacological dataset analysis |
| Q42569032 | Ventricular arrhythmias after left ventricular assist device implantation |
| Q46606774 | beta-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. |
| Q41917803 | beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress |
| Q40034384 | beta-arrestin-biased agonism at the beta2-adrenergic receptor |
| Q35804809 | beta-arrestins: traffic cops of cell signaling |
| Q28582523 | {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism |
| Q38742275 | β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. |
| Q54357047 | β-Adrenoceptors differentially regulate vascular tone and angiogenesis of rat aorta via ERK1/2 and p38. |
| Q37902725 | β-Arrestin-Biased Signaling by the β-Adrenergic Receptors |
| Q34716806 | β-Arrestin: A signaling molecule and potential therapeutic target for heart failure |
| Q36211207 | β-Blockers have differential effects on the murine asthma phenotype |
| Q61799899 | β-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-β in stroke |
Search more.